Skip to main content
ASPHO Logo
Menu Journal My Account Contact Join/Renew
Login
  • Meetings & Events
    • Conference
      • 2025 Conference
      • Continuing Education
      • Press | 2018 Conference
      • 2018 Call for Papers and Posters
        • Back to Meetings
        • 2019 Conference
        • Schedule of Events
        • Registration Rates
        • Conference Planning Committee
        • Conference Hotel and Travel
        • Faculty
        • 2019 Call for Papers and Posters
        • Continuing Education
        • PBMTC
        • Accepted Papers and Posters
        • MOC Opportunities
        • App - Thank you for Attending
        • 2019 Attendee List
      • 2018 Conference
        • Schedule of Events
        • Accepted Papers and Posters
      • 2016 Annual Meeting
        • Overview
        • Attendee List
        • ASPHO Virtual Bag
        • Corporate Forum Symposia/Education Theaters
        • Accepted Papers and Posters
          • Accepted A-G
          • Accepted H-M
          • Accepted N-Z
          • 2016 Searchable Abstract Database
        • Exhibit Hall
        • Sponsors
        • Annual Meeting Brochure
        • Virtual Bag
        • Schedule of Events
        • Continuing Education
        • Attendee List
        • 2017 Searchable Abstract Database
        • Accepted Papers and Posters
        • Corporate Forum Symposia/Education Theater
        • Travel
        • Program Committee
        • Commercial Support
        • Exhibit with ASPHO
      • Registration
      • Commercial Support
      • Meetings Archive
      • Registration Information
      • 2026 Conference
      • 2026 Call for Workshops
    • Review Course
      • Anderson 2019
      • McClain 2019
      • Adams 2019
      • Moran 2019
      • Effinger 2019
      • Fangusaro 2021
      • Brown 2021
      • Young 2021
      • Harker-Murray 2021
      • Effinger 2021
      • Pai 2021
      • Grace 2021
      • Rogers 2021
      • Anderson 2021
      • Powers 2021
      • McClain 2021
      • Neunert 2021
      • Fleming 2021
      • Mullen 2021
      • Pommert 2021
      • Meade 2021
      • Greengard 2021
      • Fox 2021
      • Bercovitz 2021
      • Brock 2021
      • Adams 2021
      • Loh 2021
      • O'Brien 2021
      • Walterhouse 2021
      • Pulsipher 2021
      • Oberley 2021
      • Rodriguez-Galindo 2021
      • Kesselheim 2021
      • Frei-Jones 2021
      • Allen 2021
      • 2015 Online Review Course CME Certificates
      • 2019 Planning Committee
      • 2019 Schedule
      • 2019 Travel
      • 2019 Review Course Early Career
      • 2019 Review Course Directors
        • 2019 Review Course Faculty
      • Oberley 2019
      • O'Brien 2019
      • Pai 2019
      • Pulsipher 2019
      • Rodriguez-Galindo 2019
      • Rogers 2019
      • Walterhouse 2019
      • Young 2019
      • Park 2019
      • Malec 2019
      • Evaluations
      • Brown 2019
      • Allen 2019
      • Fangusaro 2019
      • Fleming 2019
      • Frei-Jones 2019
      • Grace 2019
      • Harker-Murray 2019
      • Heeney 2019
      • Kesselheim 2019
      • Loh 2019
      • Mascarenhas 2019
      • Neunert 2019
      • Fangusaro 2023
      • Adams 2023
      • Neunert 2023
      • Oberley 2023
      • Grace 2023
      • Effinger 2023
      • Nakano 2023
      • Brock 2023
      • Harker-Murray 2023
      • Meade 2023
      • Fleming 2023
      • Kesselheim
      • Kumar 2023
      • Anderson 2023
      • Malogolowkin 2023
      • Pommert 2023
      • Bercovitz 2023
      • Frei-Jones 2023
      • O'Brien 2023
      • Pai 2023
      • Young 2023
      • Fox 2023
      • Powers 2023
      • Pulsipher 2023
      • McClain 2023
      • Loh 2023
      • Greengard 2023
      • Frazier 2023
      • Brennan 2023
      • Walkovich 2023
      • Browning 2023
      • Mullen 2023
      • 2025 Review Course
        • 2025 Faculty
        • 2025 Learning Objectives and CME
        • 2025 Schedule
        • 2025 Cancellation Policies and Disclosures
        • 2025 Planning Committee
        • Young 2025
        • Bercovitz 2025
        • Brennan 2025
        • Fangusaro 2025
        • Fox 2025
        • Frazier 2025
        • Greengard 2025
        • O'Brien 2025
        • Pommert 2025
        • Powers 2025
        • Pulsipher 2025
        • Walkovich 2025
        • Neunert 2025
        • Adams 2025
        • Oberley 2025
        • Grace 2025
        • Effinger 2025
        • Nakano 2025
        • Brock 2025
        • Harker-Murray 2025
        • Meade 2025
        • Fleming 2025
        • Kesselheim 2025
        • Kumar 2025
        • Creary 2025
        • DeNardo 2025
        • Dome 2025
        • Jordan 2025
        • McCavit 2025
        • Pai 2025
        • Raetz 2025
        • Malogolowkin 2025
        • Terrell 2025
        • Kucine 2025
      • Learning Objectives and CME
      • Faculty
      • Schedule
      • Policies
    • Events Calendar
  • Knowledge Center
    • Products
      • KARE Toolkit: Knowledge and Assessment Resources
        • CME for KARE
        • CME for RC On-Demand
        • CME for PHO Review Course On Demand
        • CME for KARE Plus
        • CME for KARE Plus Hematology
        • CME for KARE Plus Oncology
        • The KARE Toolkit - Index of Topics
      • Webinars
      • ASPHOcast
      • Alexion Recording
      • 2024 Compensation Survey
      • Webinar Toolkit
      • Compensation and Benefits Report
      • View the Compensation and Benefits Survey Report
      • Compensation Tool
    • Online Review Course
    • Pediatric Blood & Cancer
      • Access Journal
      • Online Access Instructions
    • ASPHO eNews
      • August 2015 Enews
      • June 2015 Enews
      • April 2015 Enews
      • February 2015 Enews
      • December 2014 Enews
      • October 2014 Enews
      • August 2014 Enews
      • June 2014 Enews
      • April 2014 Enews
      • February 2014 Enews
      • December 2013 Enews
      • October 2013 Enews
      • August 2013 Enews
      • June 2013 Enews
      • April 2013 Enews
      • February 2013 Enews
      • October 2014 Enews
      • October 2015 Enews
      • December 2015 Enews
      • February 2016 Enews
      • April 2016 Enews
      • June 2016 Enews
        • DSIG Student Registration
      • August 2016 Enews
      • October 2016 Enews
      • December 2016 Enews
      • February 2017 Enews
      • April 2017 Enews
      • June 2017 Enews
      • August 2017 Enews
      • October 2017 Enews
      • December 2017 Enews
      • February 2018 Enews
      • April 2018 Enews
      • June 2018 Enews
      • August 2018 eNews
      • October 2018 eNews
      • February 2019 eNews
      • Member Insights: eNews 2018 Highlights
      • April 2019 eNews
      • June 2019 eNews
      • August 2019 eNews
      • October 2019 eNews
      • December 2019 eNews
      • February 2020 eNews
      • April 2020 eNews
      • June 2020 eNews
      • August 2020 eNews
      • October 2020 eNews
      • December 2020 eNews
      • April 2021 eNews
      • June 2021 eNews
      • August 2021 eNews
        • August 2021 President's Message
      • December 2021 eNews
      • February 2022 eNews
      • April 2022 eNews
      • June 2022 eNews
      • August 2022 eNews
      • October 2022 eNews
      • December 2022 eNews
      • February 2023 eNews
      • April 2023 eNews
      • June 2023 eNews
      • October 2023 eNews
      • December 2023 eNews
      • February 2024 eNews
      • March 2024 eNews
      • April 2024 eNews
      • June 2024 eNews
      • August 2024 eNews
      • October 2024 eNews
      • December 2024 eNews
      • February 2025 eNews
      • April 2025 eNews
      • June 2025 eNews
    • Pediatric Blood & Cancer - Call for Applications for Deputy Editor
    • October 2015 Enews
    • Advocacy Sample
    • News Briefs
    • Health Policy & Advocacy
      • 2016 August Advocacy Brief
      • 2016 December Advocacy Brief
      • 2017 February Advocacy Brief
      • 2017 May Advocacy Brief
      • 2017 September Advocacy Brief
      • 2017 November Advocacy Brief
      • 2018 Advocacy Brief - March
      • Contact Your Members of Congress
      • 2018-Advocacy-Brief-June
      • 2018-Advocacy-Brief-September
      • Advocacy Brief December 2018
      • 2019 Advocacy Brief - March
      • March 2019 Advocacy Brief
      • June 2019 Advocacy Brief
      • September 2019 Advocacy Brief
      • March 2020 Advocacy Brief
      • June 2020 Advocacy Brief
      • September 2020 Advocacy Brief
      • December 2020 Advocacy Brief
      • June 2021 Advocacy Brief
      • September 2021 Advocacy Brief
      • March 2022 Advocacy Brief
      • June 2022 Advocacy Brief
      • September 2022 Advocacy Brief
      • March 2024 Advocacy Brief
      • September 2024 Advocacy Brief
      • December 2024 Advocacy Brief
      • March 2025 Advocacy Brief
    • 2017 Workforce Survey Report
    • Help Fund the STAT Act
    • Practice and Quality
      • Choosing Wisely®
      • Position Paper
      • Endorsements
      • ASPHO Endorsements member only
  • Career Development
    • Mentoring
      • Early Career Mentoring
    • Awards
      • Distinguished Career Award
      • Oski Memorial Lectureship
      • International Travel Awards
      • Buchanan Lectureship
      • Young Investigator Award
      • Young Investigator Form
      • EC Travel Stipend Form
      • Early Career Travel Stipend
      • Advanced Practice Provider Award
      • Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship
    • Career Center
    • Fellowship Resources
      • Post-PHO Fellowship Program Directory
      • Fellowship Program Directors' Resources
    • Certification
      • Continuing Medical Education
      • advocating for moc
      • ABP MOC Letter Nov 2015
      • ABP Hematology/Oncology Content Outline
    • 2019 ASPHO Award Recipients
    • Workforce
  • Membership
    • Who Belongs
    • Benefits
    • Join Us
    • Renew
    • Membership Application
    • Fellows Group Application
    • Member Community
    • Find a Member
    • Special Interest Groups
      • Adolescent and Young Adult SIG
      • Advanced Practice Provider SIG
      • Cancer Predisposition SIG
      • Clinical Immunology SIG
      • Diversity SIG
        • 2017 DSIG Travel Award
      • Global Hem Onc SIG
      • Hemoglobinopathy SIG
      • Hospitalist Medicine SIG
      • Informatics, Innovation and Entrepreneurship SIG
      • Integrative Pediatric Hematology/Oncology SIG
      • Palliative Care SIG
      • Physician Scientist SIG
      • Quality Improvement and Patient Safety SIG
      • Small Program SIG
      • Vascular Anomalies SIG
      • Clinical Immunology SIG Webinar
      • Well-Being SIG
    • Enriching the Future
      • ETF Donors
      • ETF FAQ
      • ETF Programs
      • ETF Award Recipients
      • Donate
    • Stay Connected with ASPHO
    • New Member
    • Trainee Membership Level
    • Strengthen Your Everyday Practice
  • About
    • Governance
      • 2017 Election Nominations
      • 2019 Board and Nominating Committee members
      • Board of Trustees
      • Leadership Development & Election Process
      • Nominating FAQs
      • Strategic Plan
        • Leadership Domain
        • Education Domain
        • Career Domain
        • Administration Domain
      • Volunteer Opportunities
        • Early Career Council
    • Policies
      • Advertising Sponsorship
      • Support of CME
      • Committee Policies, Responsibilities, and Resources
      • Conflict of Interest and Disclosure for Volunteers
      • Distinguished Career Award Eligibility Criteria
      • Diversity Statement
      • Investment
      • Member Mailing List
      • Oski Eligibility Criteria
      • Presidential Stipend
      • Records Retention
      • Reserve Fund
      • Reviews and Endorsements
      • Speaker Reimbursement
      • Surveying Members
      • Whistleblower
      • Workshop Session
      • Young Investigator Award
      • Early Career Travel Stipend
      • Buchanan Lectureship Eligibility
      • ASPHO Statements
    • Terms of Use
    • Contact Us
    • 2016 Election Nominations
    • 2015 Election Candidates
    • FDA Approves Dinutuximab
    • Q&A Amy Billett
    • Fund Raising Policy
    • Support and Advertising
      • Exhibit
      • Advertising
      • Industry Relations Council
      • Grants
    • Diversity & Inclusion
    • Donate
    • DEI Member Perspectives
    • Account Access
  • 2017 Annual Meeting Session Recordings
  • 2018 Annual Meeting Session Recordings
  • George R. Buchanan Lectureship Award Presentation
  • Cancer Predispositions in Clinical Practice
  • Evidence and Equipoise in Pediatric Thrombosis - Updates from Randomized Controlled Trials
  • Playing on Our Strengths - Developing Interprofessional Teams in Pediatric Hematology-Oncology
  • Providing Optimal Pediatric Palliative Care: Overcoming the Barriers
  • When in Quebec, Do What the Quebecers Do (Part Deux) - It's All About Platelets!
  • Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Pediatric Patients with ALL in the era of Tyrosine Kinase Inhibitors, Novel Immunotherapies and 'MRD Status'
  • Award Presentations
  • Hemophilic Arthropathy, More Than Meets the Eye: Advances in Early Disease Detection from Clinical Tools to Musculoskeletal Imaging
  • ZFNs, CrispR/Cas9 and TALENS- Oh My!
  • Collaboration in the Treatment of Liver Tumors
  • Leukemia
  • Solid Tumors/Lymphoma
  • Hematology I
  • Beyond Antibodies and CAR T Cells: Challenges and Opportunities in Manipulating the Pediatric Cancer Immunome
  • Blood Clots in Sick Kids: A critical mini-review of venous thrombo-embolism in selected high-risk pediatric populations
  • It's not just about Diversity: Improving the Outcomes for All by Moving toward Equity
  • Children's Oncology Group (COG)
  • Outcomes Research
  • Social Media: The Good, The Bad, and Beyond
  • Sickle Cell Disease in the AYA population: Management Challenges for the Pediatric Hematologist
  • Molecularly Defined Rare Pediatric Sarcomas: An Update for the General Oncologist
  • Mechanisms of Tumor Microenvironment Immune Mediated Resistance and Methods of Therapeutic Circumvention
  • Behind the Scenes at Pediatric Blood & Cancer: Everything You Always Wanted to Know About Getting Published
  • New Insights in Inherited Hematologic Diseases
  • Changing Workforce of Pediatric Hematology/Oncology
  • New Diagnostic and Therapeutic Approaches of Opportunistic (Viral/Fungal) Infections in the Pediatric Cancer Patient
  • New Mutations and Targeted Therapies in Langerhans Cell Histiocytosis
  • Physician, Sustain Thyself: Building Resilience to Prevent Burnout
  • Practicing Precision in Pediatric Oncology: Three Perspectives
  • What's Happening in DC? A Look at ASPHO Advocacy Efforts
  • Critical Care of the Immunocompromised Pediatric Hematology/Oncology Patient
  • Brain Tumors
  • Hematology II
  • Sponsor, Exhibit, and Advertise
    • Exhibits
    • Advertising
    • Industry Relations Council
    • Exhibits Adveritising
  • Ward Testing OSE
  • 2018 Session | George R. Buchanan Lectureship Award Presentation
  • 2018 Session | Plenary Paper Session 2001-2002
  • 2018 Session | St. Baldrick's Foundation Robert J. Arceci Innovation Award Announcement
  • 2018 Session | Plenary Session—Health Care in the Current Political Climate: Stormy Days Ahead?
  • 2018 Session | Pediatric Ependymoma: The Science Driving Patient Care
  • 2018 Session | Iron: Let's Get Pumped
  • 2018 Session | Extracellular Vesicle Trafficking—Biology and Translational Impact in Hematology and Cancer
  • 2018 Session | Relapsed, Refractory, Metastatic Bone Sarcomas: New Insights on Pathogenesis, Prognosis and Treatment
  • 2018 Session | Alpha Thalassemia—A Growing Public Health Disease with Changing Landscape of In-Utero and Post-Natal Therapy
  • 2018 Session | Decision Making in Benign Hematology: Living in a World Without Randomized Trials
  • 2018 Session | Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship
  • 2018 Session | Early Career Travel Stipend Awards
  • 2018 Session | Young Investigator Award Presentations
  • 2018 Session | Management of Extracranial Germ Cell Tumors in Adolescent and Young Adult Population
  • 2018 Session | Challenging Hematologic Complications Post–Stem Cell Transplantation and Beyond
  • 2018 Session | Advanced Symptom Management and End-of-Life Care: Multidisciplinary Primary Palliative Care for Pediatric Hematologists/Oncologists
  • 2018 Session | Paper Session - Solid Tumor
  • 2018 Session | Paper Session - Hematology
  • 2018 Session | Vascular Anomalies: The Great Mimickers
  • 2018 Session | Addressing Sexual Health in Adolescent and Young Adult Patients: What You Should Know as a Pediatric Hematology/Oncology Care Provider
  • 2018 Session | Navigating Intravascular Bottlenecks: A Critical Mini-Review of Pediatric Venous Thromboembolism in the Setting of an Anatomical Thrombophilia
  • 2018 Session | Paper Session - Children's Oncology Group (COG)
  • 2018 Session | Paper Session - Hematology Science
  • 2018 Session | Can Late Effects be Prevented in Pediatric Oncology?
  • 2018 Session | Clash of the Titans: Debates on Best Management of Patients with Bleeding Disorders
  • 2018 Session | Providing Effective Feedback: The Currency of Conflict Resolution
  • 2018 Session | Recent Advances and New Approaches to Rare Hematological Malignancies
  • 2018 Session | Primary and Secondary Stroke Prevention in Sickle Cell Disease: The Debate
  • 2018 Session | Combating an Unmet Need: Psychosocial Health
  • 2018 Session | Renal Tumors Beyond Wilms
  • 2018 Session | Pediatric and Neonatal Transfusion Medicine
  • 2018 Session | Mobile Applications in Clinical Practice
  • 2018 Session | Presidential Symposium—Partnering with Patients and Families to Improve Research and Clinical Decision-making
  • 2018 Session | Review of Rare Pediatric Head and Neck Tumors for the General Oncologist
  • 2018 Session | Emerging Therapies in Hemophilia
  • 2018 Session | How Should You Treat That Bug? A Debate About Antimicrobial Management in Fever and Neutropenia
  • 2018 Session | Paper Session with Luminary Investigator - Leukemia
  • 2018 Session | Paper Session with Luminary Investigator - Hematology
  • 2018 Session | Frank A. Oski Memorial Lectureship Award Presentation
  • December 2018 eNews
  • 2019 Session | Splenectomy - The Great Debate
  • 2019 Session | DICER1: Updates on Biology and Clinical Management
  • 2019 Session | Burnout in Pediatric Hematology/Oncology: Moving from Discussion to Action
  • 2019 Session | Diagnostic and Management Conundrums Surrounding Women with Heavy Menstrual Bleeding and Underlying Bleeding Disorders
  • 2019 Session | All That Glitters is Not Gold – How We Differentiate Primary HLH from Fake News
  • Models for International Pediatric Oncology Outreach
  • 2019 Session | Navigating Genetic Testing in the Pediatric Hematology Setting
  • 2019 Session | Radiation Therapy for Pediatric Cancer Patients: Updates and New Modalities
  • 2019 Session | The Microbiome: What Is It and Why Do We Care?
  • 2019 Session | Brain Attack: Therapeutic Advances in Neonatal and Childhood Stroke
  • 2019 Session | Advances in Pediatric AML
  • 2019 Session | Improving Medication Adherence for Adolescents and Young Adults: Is Technology the Answer?
  • 2019 Session | Metabolism in Pediatric Hematology/Oncology - Presidential Symposium
  • 2019 Session | Too Much of a Good Thing – Myeloproliferation in Children
  • 2019 Session | Multiple Bony Lytic Lesions, but Not Langerhans Cell Histiocytosis (LCH) – Now What?
  • 2019 Session | Savior Siblings: Medical, Ethical, and Psychosocial Considerations in using Preimplantation Genetic Diagnosis (PGD) to Ensure a Matched Sibling Donor for Hematopoietic Stem Cell Transplantation (HSCT)
  • 2019 Session | George R. Buchanan Lectureship Award Presentation
  • 2019 Session | 2019 St. Baldrick’s Foundation Robert J. Arceci Innovation Award Announcement and Past Recipient Presentation
  • 2019 Session | Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship Announcement and Frank A. Oski Memorial Lectureship Award Presentation
  • 2019 Session | New Paradigms for Severe Aplastic Anemia: Genetic Screening, Eltrombopag, and Up Front Unrelated Donor BMT
  • 2019 Session | Not Too Young for That Cancer: Adolescent and Young Adult Carcinomas
  • 2019 Session | Transforming the Treatment of Chronic Pain
  • 2019 Session | Putting an End to End Organ Damage in Sickle Cell Disease
  • 2019 Session | Defining Pediatric MDS: A Morphologic or Molecular Diagnosis?
  • 2019 Session | The Power of One: Present Challenges in Treating Rare Diseases
  • 2019 Session | Hematological Manifestations of Immune Deficiencies and Dysregulatory Disorders: When should you look harder for underlying causes of Autoimmune Cytopenias?
  • 2019 Session | Oncofertility Programs: More Than Just Sperm Banking
  • 2019 Session | The (Financial) Cost of a "Cure"
  • 2019 Session | (2001) Potential Utility of MRD to Identify Relapse in pALL Patients Treated with Tisagenlecleucel
  • 2019 Session | (2002) Lentiglobin Gene Therapy in Transfusion-Dependent Β-Thalassemia Patients with Non-β0/β0 Genotypes
  • 2019 Session | (2003) Mechanisms of Resistance to the Type II JAK2 Inhibitor CHZ868 in B-Cell Acute Lymphoblastic Leukemia
  • 2019 Session | (2004) Discovering Noncoding Genetic Elements that Regulate Globin Synthesis
  • 2019 Session | (2005) Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis: Safety & Efficacy
  • 2019 Session | (2006) Modeling IKZF1 Lesions in B-cell Acute Lymphoblastic Leukemia Reveals Potential Therapeutic Targets
  • 2019 Session | (2007) Prognostic Determinants in Childhood T-cell Acute Lymphoblastic leukemia: Results of DFCI 05001
  • 2019 Session | (2008) Gap Junction Interference increases Apoptosis in ALL cells and augments effects of Antimetabolites
  • 2019 Session | (2009) Hydroxyurea Lowers Tricuspid Regurgitant Jet Velocity in Children with Sickle Cell Anemia
  • 2019 Session | (2010) Novel Next-Generation Sequence based Assay for Non-Invasive Prenatal Testing of Sickle Cell Disease
  • 2019 Session | (2011) Gabapentin for Pain in Sickle Cell Disease: Results of a Randomized Phase II Clinical Trial
  • 2019 Session | (2012) Quality of Life is the most important Indication for Second-Line ITP Treatment in Children
  • 2019 Session | (2013) BCL2-Inhibitor Response in Neuroblastoma: Biomarkers and Therapy Resistance
  • 2019 Session | (2014) The Clinical Application of Molecular Testing in Pediatric Solid Tumors: An Institutional Experience
  • 2019 Session | (2015) Enhancing Tumor Directed T Cells with an Interleukin-7 Signal Modulator
  • 2019 Session | (2016) Epigenome Screening Identifies Transcriptional Elongation as Therapeutic Vulnerability in DIPG
  • 2019 Session | (2017) Levofloxacin Prophylaxis
  • 2019 Session | (2018) Renal Tumors: Future Roadmap
  • 2019 Session | (2019) Soft Tissue Sarcoma
  • 2019 Session | (2020) Realizing Effectiveness across Continents with Hydroxyurea (REACH): A Prospective Multi-National Trial of Hydroxyurea for Sickle Cell Anemia in Sub-Saharan Africa
  • 2019 Session | (2021) Leucine for the Treatment of Transfusion Dependence in Patients with Diamond Blackfan Anemia
  • 2019 Session | (2022) A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds
  • 2019 Session | (2023) Peripherally Inserted Central Catheters (PICCs), the Leading Cause of Central Venous Catheter Associated Thrombosis in Children
  • 2019 Session | The Role of Survivorship Research in Advancing Childhood Cancer Care and Quality of Survival
  • 2019 Session | (2024) Septic Shock (SS) Incidence in National ALL & AML Cohorts using Administrative & Clinical Trial Data
  • 2019 Session | (2025) Nelarabine Abrogates Relapse Rates in CNS-3 T-ALL: A Report from Children’s Oncology Group AALL0434
  • 2019 Session | (2026) Current Cancer Survivorship Practices: A Report from the Children’s Oncology Group (COG)
  • 2019 Session | (2027) Intra-Arterial Chemotherapy for Retinoblastoma: A 7-year Single Institution Experience
  • 2019 Session | Advancing Discovery in Hematology: Bench to Bedside? No. Bedside to Bench to Bedside...
  • 2019 Session | (2028) The Shwachman Diamond Syndrome Registry: Hematologic Complications
  • 2019 Session | (2029) Characteristics and Outcomes of Unprovoked Venous Thromboembolism in the Pediatric Population
  • 2019 Session | (2030) Third Party VST are an effective Therapy for the Treatment of BK-Virus Reactivation after Transplant
  • 2019 Session | (2031) Inhibition of Nemo-Like Kinase improves Erythropoiesis in Models of Diamond Blackfan Anemia
  • CI SIG Webinar
  • October 2021 eNews
  • 2025 Conference App Download Instructions

ASPHO16 Advocacy web 

March 2025

The ASPHO Advocacy Brief

Welcome to the Advocacy Brief, a quarterly offering from the American Society of Pediatric Hematology/Oncology. The goal of this newsletter is to inform members about legislative and regulatory issues impacting the profession of pediatric hematology/oncology and the patients we serve. Visit ASPHO’s Health Policy & Advocacy webpage for updates on sign-on letters, legislative efforts, and more information to support pediatric hematology/oncology advocacy.

A Brief Message

As a new administration moved into power on January 20, 2025, we have seen a flurry of executive activity that can have a great impact on the work of ASPHO members and your patients. As these actions continue to come at a rapid pace they cause confusion that can impact the most vulnerable pediatric hematology/oncology patients and their families. Through all of this instability, we want our members to know that ASPHO remains committed to our advocacy priorities. We continue to monitor and take action with our coalition partners to ensure the voices of PHO physicians are heard and have an impact.

At the end of each featured article in this month’s Advocacy Brief, you will find opportunities to take action with your members of Congress. We ask that if you have not already done so, you use your voice to make sure policy makers know the real-world impact of the actions they are taking.

As things move forward, ASPHO will continue to sift through the noise and keep you informed on issues of importance. We would also invite you to join us at the Business Meeting during conference in Louisville, as we will be providing you all with an update on advocacy efforts at that time.

*Send your health policy and advocacy news to ASPHO This email address is being protected from spambots. You need JavaScript enabled to view it. .

ASPHO Bill Tracker

Visit ASPHO’s Legislative Tracking Chart to see a list of bills that ASPHO is monitoring.

Special Feature Articles

Children’s Oncology Group Provides Value to Pediatric Cancer Research

By David Dickens, MD FAAP, Clinical Professor and Director, Pediatric Hematology, Oncology, and Bone Marrow Transplantation, University of Iowa Dance Marathon Endowed Chair in Clinical and Translational Research

Every other day, a child in Iowa is diagnosed with cancer. Despite their diverse demographic and socioeconomic backgrounds, they all share the same fundamental wish: to survive. Ideally, they would receive the best available treatments close to home, while experiencing no short- or long-term side effects. As aspirational as this goal may seem, it is what patients hope for and what their providers strive toward. However, the reality remains stark—we continue diagnosing incurable diseases while permanently harming many of those we can cure. The only way to bridge this gap is through research.

A clear example of research-driven progress is the development of blinatumomab for B-cell acute lymphoblastic leukemia (B-ALL). In 2019, the Children’s Oncology Group (COG) launched a phase 3, randomized controlled trial, incorporating blinatumomab into a standard chemotherapy regimen—one refined through decades of prior research. Over five years, this trial enrolled more than 4,000 patients and was closed early due to an interim analysis demonstrating that adding blinatumomab improved three-year event-free survival rates by nearly 10% (87.9% to 96%).

The University of Iowa enrolled 23 patients in that trial. Because of this study, one of them—who otherwise might not have survived—will now be cured. If this trial had been conducted solely in Iowa, it would have taken over 200 years to reach the same conclusion. This is just one life saved through a collaborative, nationwide effort—and many more will follow. It is a testament to the power of cooperative research groups like COG, which have been driving pediatric cancer advancements for decades.

Founded in 2000 through the merger of earlier pediatric cancer research groups, the Children’s Oncology Group is the largest organization in the world dedicated exclusively to childhood and adolescent cancer research. Supported by the National Cancer Institute (NCI), COG unites more than 200 hospitals and institutions across North America, Australia, New Zealand, and parts of Europe. Its mission is to design and oversee clinical trials that ensure new treatments are both effective and safe. Beyond research, COG provides crucial educational resources for families navigating childhood cancer, offering guidance on treatment options, survivorship, and late effects of therapy.

The impact of publicly funded research is undeniable. A recent study on NCI-sponsored phase 3 clinical trials in adult cancer found that most led to new standards of care, generating over 14 million additional life years at an average cost of just $320 per life-year gained. While a similar study on COG trials has yet to be conducted, given the younger average age of pediatric cancer patients and the high cure rates achieved through research, the return on investment is likely even greater.

Yet, for many childhood cancers, cure rates remain unacceptably low, and new treatments are urgently needed. Because pediatric cancers are rare, progress depends on collaboration, which in turn requires sustained investment. Without ongoing national commitment to rigorous, cooperative clinical trials, progress will stall, and children will continue to die—or survive with debilitating long-term effects from their treatment.

At this critical juncture, funding for pediatric cancer research—and pediatric care more broadly—is at risk, and critical funding for research continues to be in jeopardy. Pediatric oncologists have long been fierce advocates for their patients within their institutions and communities. Now, it is imperative to extend that advocacy to the broader field of pediatric oncology.

I have had the privilege of working alongside some of the most dedicated individuals through organizations such as the American Society of Pediatric Hematology/Oncology, the American Academy of Pediatrics, the American Society of Clinical Oncology, and the Alliance for Childhood Cancer. These groups, and many others, provide avenues for advocacy at both state and federal levels, from emails and phone calls to in-person meetings with legislators. The most powerful messages often emerge when providers and families unite to share their experiences.

For those new to advocacy, the first step is understanding your institution’s guidelines for engagement. While advocacy is time-consuming and does not generate revenue, it is profoundly impactful. Even on its most frustrating days, it is more rewarding than the worst days in the clinic.

I often wonder which of my patients was saved because of this NCI-sponsored COG blinatumomab trial. That thought fuels my drive to advocate for more breakthroughs like it. At the same time, I fear the regret of living in a world where progress in pediatric cancer care stagnates—and knowing I didn’t even try to change it.

Take action today to let your members of Congress know you support ongoing investment into the National Institutes of Health.

AACR Action Alert to Support Medical Research
ASH Action Alert to Support Research Funding


A Threat to Funding, a Threat to Children: A Pediatric Hematologist’s Perspective

By Taizo Nakano, MD, Children’s Hospital Colorado, ASPHO Advocacy Committee Member

As pediatric hematologists, we face an array of life-threatening blood disorders and accept the challenge to cure the incurable. We stand on the shoulders of a molecular renaissance that has helped unlock the secrets of rare disease and has transformed our clinical landscape from one of hopes and dreams to one of evidence-based cure. From congenital dyserythropoietic anemia to hemophagocytic lymphohistiocytosis, rare pediatric blood disorders can be difficult to understand, challenging to study and even harder to pronounce.

With few independent foundations and philanthropic funding programs dedicated to pediatric blood disorders, our field has depended, more than most, on partnership from the nation’s top supporter of innovative and life-saving science, the National Institute of Health (NIH). NIH grant funding is our critical artery that promotes creativity, feeds innovation, and allows our scientists and clinicians to lead the world’s race towards cure. With respect for the critical nature of this funding, we compete for it. We push boundaries for it, we don’t eat or sleep for it, we’ll bleed for it. And when policy threatens the stability of NIH funding and the lives of our pediatric patients, we will vigorously oppose it.

Of course, much of this has already happened and the ground is still shaking. Grant reviews have already been canceled; submissions no longer accepted. Reagents expire, critical cell-lines exhaust and, most importantly, the light within of a generation of young physician scientists is dimming. Still, so long as our cells carry oxygen, we continue to aim to cure the incurable because there are immunocompromised children stuck in hospitals across the country right now waiting for us; parents desperately depending on us. We hope that our effort is strong enough to anastomose political divide, advance our field, and save their lives. We will continue to push boundaries regardless and continue to support national and federal collaboration because, as pediatric hematologists, your children are depending on us.


Take action today to let your members of Congress know you support ongoing investment into the National Institutes of Health.

AACR Action Alert to Support Medical Research
ASH Action Alert to Support Research Funding


ASPHO Participates in the Alliance for Childhood Cancer Action Days 2025

By Zachary D. Prudowsky, MD, ASPHO Advocacy Committee Member and Liaison to the Alliance for Childhood Cancer

The Alliance for Childhood Cancer (Alliance) is a consortium of over 20 professional and philanthropic organizations all with the same collective goal – to improve the lives of children and families affected by childhood cancer through policy. Every year, the Alliance hosts Action Days, an event where volunteers from all over the country converge in Washington D.C. to meet with legislators to advocate for bills and appropriations to advance research and access to care. This year, I represented ASPHO along with Karen Effinger, MD MS, Associate Professor of Pediatrics, Emory University, Co-Director, Survivor Program, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta.

The early months of our new government have been controversial, with the executive branch leading spending cuts that threaten the infrastructure of pediatric cancer care in America. In response, an overwhelming amount of volunteers signed up to join Action Days, forcing online registration to close early and testing the limits of the fire code capacity in the Marriott Metro Center conference hall. Approximately 350 people from 40 states came to D.C., meeting with 222 separate members of Congress and the House of Representatives. Many of the advocates survived childhood cancer and were there to seek better treatments for the next generation, or bereaved parents who lost their child to cancer, approaching Capitol Hill wishing there were better available treatments. All got to share their stories and make an impact.

The agenda for Action Days focused around 3 priorities:

  1. Co-sponsor childhood cancer legislation: Multiple influential bills on the Alliance’s radar were unfortunately left off of the 2024 year-end budget resolution, and all except for the Gabriella Miller Kids First Research Act (which was passed outside of the budget bill) are still on the table for action this year. The Alliance gave an unofficial nickname to this series of policies, naming it the “Childhood Cancer Package.” Included in this package are the Accelerating Kids Access to Care Act (AKACA), the Give Kids a Chance Act, the Retaining Access and Restoring Exclusivity (RARE) Act, the Creating Hope Reauthorization Act, and the Innovation in Pediatric Drugs Act. The AKACA and Give Kids a Chance Act have been reintroduced in the House and Senate, while the Innovation in Pediatric Drugs Act has been reintroduced in the Senate. ASPHO has endorsed all of these bills.
  2. Prioritize appropriations to the National Institutes of Health: In previous years, the Alliance has been on Capitol Hill advocating for higher budgeting and appropriations for the National Institutes of Health (NIH). This year, it is dire to ensure federal funding is maintained, as cuts threaten to shrink overall NIH funding and infrastructure, the results of which could have devastating impacts towards pediatric cancer research and access to clinical trials. The Alliance asked Congress for continued and uninterrupted NIH support, and to maintain funding to the Childhood Cancer Survivorship, Treatment, Access, Research (STAR) Act and the Childhood Cancer Data Initiative (CCDI).
  3. Avoid cuts to Medicaid that would restrict access to childhood cancer care: The House of Representatives passed a budget resolution outlining their priorities for the fiscal year (FY) 2026 budget, just days prior to Action Days. In it were proposed cuts to Medicaid aimed to address “waste, fraud, and abuse.” Alliance advocates reminded members of Congress that 50% of the nation’s children are on Medicaid, and that there is nothing wasteful, fraudulent, or abusive about ensuring access to care for children with cancer.

The Alliance will continue to directly advocate on these important issues. Meanwhile, any and all members of ASPHO are encouraged to contact their Senators and Representatives directly to ensure these efforts continue to be a priority for them to address as soon as possible. Meanwhile, feel free to use these online tools to identify and contact your members of Congress:


Take action today to let your members of Congress know your thoughts on investing in NIH and protecting the Medicaid program.

AACR Action Alert to Support Medical Research
ASH Action Alert to Support Research Funding
ACS-CAN Action Alert on Medicaid Cuts


Legislative/Regulatory News

Continuing Resolution Passes to Avoid Government Shut Down

In order to avoid a government shut down, Congress passed, and President Trump signed, a Continuing Resolution (CR) on March 14. This CR will fund the government through September 30, 2025, which is the end of federal fiscal year (FY) 2025. Funding for the National Cancer Institute (NCI) was maintained at the FY 2024 level. However, there was a $859 million, or 58%, cut to the Congressionally Directed Medical Research Program (CDMRP), which includes the Peer Reviewed Cancer Research Program (PRCRP). ASPHO has consistently supported the PRCRP, urging Congress to maintain funding of the program and asking it to continue including pediatric and AYA cancers, pediatric brain tumors, neuroblastoma, sarcomas, germ cell cancers, blood cancers, lymphoma, and thyroid cancer as eligible funding topics under the program. ASPHO will continue to work with our partners at the Alliance for Childhood Cancer to work to restore funding to this important program.

Continuing Resolution vs. Budget Resolution

The process of passing the CR should not be confused with the recent passage of a budget resolution by both the House and Senate. A budget resolution is a non-binding blueprint that outlines fiscal goals but does not carry the force of law. However, you may have seen news stories with concerns about potential drastic cuts to the Medicaid program. The House budget resolution did contain language indicating they would like to make $880 billion in cuts from programs under the jurisdiction of the House Energy and Commerce Committee, this would include Medicaid. As the administration has claimed they do not wish to cut the Medicare or Social Security programs, this leaves Medicaid as the possible target of these massive cuts.

ASPHO has joined the Alliance for Childhood Cancer in opposing cuts or changes to the Medicaid program that would impede access and threaten needed coverage for children. As such massive potential cuts to Medicaid would have a disproportionate impact on pediatric patients, ASPHO will continue to monitor this important issue and provide members with additional opportunities to take action.

Sickle Cell Disease Comprehensive Care Act Reintroduced

Senator Corey Booker of New Jersey has reintroduced the Sickle Cell Comprehensive Care Act (S.721), which would expand the existing Medicaid Health Home program to allow states to submit a state plan amendment (SPA) to establish a Health Home with sickle cell disease (SCD) as the single qualifying condition for eligibility. ASPHO has previously supported this legislation which would greatly improve the care delivered to Medicaid beneficiaries living with SCD. You can read more about this legislation in our June 2024 Advocacy Brief.

Please take action today and ask your Senators to co-sponsor this important legislation.


For more information on our coalition partners and activities, visit:

American Academy of Pediatrics
Alliance for Childhood Cancer
American Society of Hematology
Sickle Cell Disease Coalition

Please visit our Health Policy & Advocacy website section for past issues of Advocacy Brief and stay up to date by following #ASPHOAdvocates on Facebook and X (formerly Twitter).

  • Products
    • KARE Toolkit: Knowledge and Assessment Resources
    • Webinars
    • ASPHOcast
    • Alexion Recording
    • 2024 Compensation Survey
    • Webinar Toolkit
    • Compensation and Benefits Report
    • View the Compensation and Benefits Survey Report
    • Compensation Tool
  • Online Review Course
  • Pediatric Blood & Cancer
    • Access Journal
    • Online Access Instructions
  • ASPHO eNews
    • August 2015 Enews
    • June 2015 Enews
    • April 2015 Enews
    • February 2015 Enews
    • December 2014 Enews
    • October 2014 Enews
    • August 2014 Enews
    • June 2014 Enews
    • April 2014 Enews
    • February 2014 Enews
    • December 2013 Enews
    • October 2013 Enews
    • August 2013 Enews
    • June 2013 Enews
    • April 2013 Enews
    • February 2013 Enews
    • October 2014 Enews
    • October 2015 Enews
    • December 2015 Enews
    • February 2016 Enews
    • April 2016 Enews
    • June 2016 Enews
    • August 2016 Enews
    • October 2016 Enews
    • December 2016 Enews
    • February 2017 Enews
    • April 2017 Enews
    • June 2017 Enews
    • August 2017 Enews
    • October 2017 Enews
    • December 2017 Enews
    • February 2018 Enews
    • April 2018 Enews
    • June 2018 Enews
    • August 2018 eNews
    • October 2018 eNews
    • February 2019 eNews
    • Member Insights: eNews 2018 Highlights
    • April 2019 eNews
    • June 2019 eNews
    • August 2019 eNews
    • October 2019 eNews
    • December 2019 eNews
    • February 2020 eNews
    • April 2020 eNews
    • June 2020 eNews
    • August 2020 eNews
    • October 2020 eNews
    • December 2020 eNews
    • April 2021 eNews
    • June 2021 eNews
    • August 2021 eNews
    • December 2021 eNews
    • February 2022 eNews
    • April 2022 eNews
    • June 2022 eNews
    • August 2022 eNews
    • October 2022 eNews
    • December 2022 eNews
    • February 2023 eNews
    • April 2023 eNews
    • June 2023 eNews
    • October 2023 eNews
    • December 2023 eNews
    • February 2024 eNews
    • March 2024 eNews
    • April 2024 eNews
    • June 2024 eNews
    • August 2024 eNews
    • October 2024 eNews
    • December 2024 eNews
    • February 2025 eNews
    • April 2025 eNews
    • June 2025 eNews
  • Pediatric Blood & Cancer - Call for Applications for Deputy Editor
  • October 2015 Enews
  • Advocacy Sample
  • News Briefs
  • Health Policy & Advocacy
    • 2016 August Advocacy Brief
    • 2016 December Advocacy Brief
    • 2017 February Advocacy Brief
    • 2017 May Advocacy Brief
    • 2017 September Advocacy Brief
    • 2017 November Advocacy Brief
    • 2018 Advocacy Brief - March
    • Contact Your Members of Congress
    • 2018-Advocacy-Brief-June
    • 2018-Advocacy-Brief-September
    • Advocacy Brief December 2018
    • 2019 Advocacy Brief - March
    • March 2019 Advocacy Brief
    • June 2019 Advocacy Brief
    • September 2019 Advocacy Brief
    • March 2020 Advocacy Brief
    • June 2020 Advocacy Brief
    • September 2020 Advocacy Brief
    • December 2020 Advocacy Brief
    • June 2021 Advocacy Brief
    • September 2021 Advocacy Brief
    • March 2022 Advocacy Brief
    • June 2022 Advocacy Brief
    • September 2022 Advocacy Brief
    • March 2024 Advocacy Brief
    • September 2024 Advocacy Brief
    • December 2024 Advocacy Brief
    • March 2025 Advocacy Brief
  • 2017 Workforce Survey Report
  • Help Fund the STAT Act
  • Practice and Quality
    • Choosing Wisely®
    • Position Paper
    • Endorsements
    • ASPHO Endorsements member only
Advertising, Exhibits, & Support | Career Center | Calendar | Contact Us
Terms of Use & Privacy Policy » © The American Society of Pediatric Hematology/Oncology®